Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6193743 | Practical Radiation Oncology | 2012 | 9 Pages |
Abstract
LAPC patients who suffer local progression following definitive CRT may experience inferior OS and increased risk of metastasis, warranting efforts to improve control of local disease. However, patients with poor pretreatment performance status, elevated CA19-9 levels, and treatment interruptions may experience poor outcomes despite aggressive management with CRT, and may optimally be treated with induction chemotherapy or supportive care. Novel therapies aimed at controlling both local and systemic progression are needed for patients with LAPC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Sonali MD, Amol K. BA, Timothy M. MD, MPH, Hao PhD, Elizabeth M. MD, Lei MD, PhD, Dung T. MD, David MD, Ralph H. MD, Elliot K. MD, Richard MD, PhD, Daniel A. MD, Christopher L. MD, PhD, Luis A. MD, Joseph M. MD, MS,